Synonym
Ro 15-2041; Ro 152041; Ro-15-2041.
IUPAC/Chemical Name
(R)-7-Bromo-1,5-dihydro-3,6-dimethylimidazo(2,1-b)quinazolin-2-(3H)-one
InChi Key
IASFSCWLFJGXQL-SSDOTTSWSA-N
InChi Code
InChI=1S/C12H12BrN3O/c1-6-8-5-16-7(2)11(17)15-12(16)14-10(8)4-3-9(6)13/h3-4,7H,5H2,1-2H3,(H,14,15,17)/t7-/m1/s1
SMILES Code
O=C1NC2=NC3=C(C(C)=C(Br)C=C3)CN2[C@@H]1C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
294.15
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Devynck MA, Le Quan Sang KH, Joulin Y, Mazeaud M. Acute membrane effects of trimetazidine in human platelets. Eur J Pharmacol. 1993 Apr 15;245(2):105-10. PubMed PMID: 8387923.
2: Mazeaud MM, Sang KH, Astarie C, Levenson J, Simon A, Devynck MA. Hypercholesterolemia modulates the effects of nitrendipine on blood pressure and platelet function in essential hypertension. J Cardiovasc Pharmacol. 1991;18 Suppl 10:S46-51. PubMed PMID: 1725003.
3: Mazeaud MM, Le Quan Sang KH, Devynck MA. Platelet cyclic AMP in essential hypertensive and normotensive offspring. J Hypertens Suppl. 1989 Dec;7(6):S148-9. PubMed PMID: 2561137.
4: Mazeaud MM, Le Quan Sang KH, Devynck MA. Platelet cyclic AMP in essential hypertension. J Hypertens. 1989 Jun;7(6):501-6. PubMed PMID: 2550542.
5: Lanza F, Beretz A, Stierlé A, Corre G, Cazenave JP. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization. Thromb Res. 1987 Mar 1;45(5):477-84. PubMed PMID: 3035738.
6: Macphee CH, Harrison SA, Beavo JA. Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6660-3. PubMed PMID: 3018742; PubMed Central PMCID: PMC386564.
7: Erne P, Mittelholzer E, Rogg H, Resink TJ, Bühler FR. Vasodilating agents and platelet function: intracellular free calcium concentration, cyclic nucleotides, and shape-change response. J Cardiovasc Pharmacol. 1986;8 Suppl 8:S102-6. PubMed PMID: 2433509.
8: Muggli R, Tschopp TB, Mittelholzer E, Baumgartner HR. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase. J Pharmacol Exp Ther. 1985 Oct;235(1):212-9. PubMed PMID: 2995647.
